Evidence map›Paper›PMID 37213874›Full record

ReviewMethodist DeBakey cardiovascular journal2023

What's New with TAVR? An Update on Device Technology.

Syed Zaid, Marvin D Atkins, Neal S Kleiman, Michael J Reardon, Gilbert H L Tang

Open access · diamondAbstract readReview
In one paragraph

Review in Methodist DeBakey cardiovascular journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Syed ZaidHouston Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, Texas, US.ORCID https://orcid.org/0000-0001-9426-3618
Marvin D AtkinsHouston Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, Texas, US.ORCID https://orcid.org/0000-0001-6619-5806
Neal S KleimanHouston Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, Texas, US.ORCID https://orcid.org/0000-0002-4334-8133
Michael J ReardonHouston Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, Texas, US.ORCID https://orcid.org/0000-0002-2880-6132
Gilbert H L TangMount Sinai Medical Center, New York, US.ORCID https://orcid.org/0000-0001-7219-990X
Houston Methodist · USMount Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last 20 years, transcatheter aortic valve replacement (TAVR) has revolutionized the management of aortic stenosis and has become the standard of care across the entire spectrum of surgical risk. Expansion of TAVR in treating younger, lower-risk patients with longer life expectancies, and treating earlier in the disease process, has seen a continuous evolution in device technology, with several next-generation transcatheter heart valves developed to minimize procedural complications and improve patient outcomes. This review provides an update on the latest advances in transcatheter delivery systems, devices, and leaflet technology.

Indexed as

Aortic Valve StenosisHeart Valve ProsthesisTranscatheter Aortic Valve ReplacementAortic ValveHumansRisk FactorsTreatment Outcomeaortic stenosisaortic valve replacementprosthetic aortic valvestranscatheter aortic valve implantation

Identifiers

PMID37213874
PMCPMC10198244
OpenAlexW4376855032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.